Information for Medical & Healthcare Practitioners
Oxford Bioscience is a UK-based biotechnology company committed to discovering and developing tailormade and safe, non-drug, therapeutic solutions and non-invasive devices for the regeneration of musculoskeletal soft tissue to significantly improve patients’ well-being. The company provides a support structure to help medical and healthcare practitioners ensure that chronic patients are guided, evaluated and followed up.
Oxford Bioscience is working in close partnership with RedPlane by interpreting data received from practitioners whose patients use Elexoma™ Medic. Results, feedback and input about the product are gathered and interpreted by Oxford Bioscience; all part of the process of ensuring that both patient and practitioner receive the best from the Elexoma™ Medic. CME, the education journal of choice for general practitioners, currently runs a series of articles on microcurrent and CES and its treatment indications, to educate doctors about the value of this innovative treatment for their patients. [OBAP certificate]
The Oxford Bioscience Accreditation Programme (OBAP)
The Oxford Bioscience Accreditation Programme (OBAP) benefits both the practitioner and patient. To comply with international Health Technology Assessment (HTA) requirements for medical devices, OBAP has been established to provide:
RedPlane offers all Oxford Bioscience-accredited medical and healthcare practitioners remuneration for evaluations and feedback on patients using Elexoma™ Medic. This feedback enables Oxford Bioscience to process the results for further research and assessment purposes. “We must use safe and cost-effective technology to achieve the goal of Quality Adjusted Life Years (QALY) for patients.” – Mr John Harvey, healthcare strategist.
Oxford Bioscience is a UK-based biotechnology company committed to discovering and developing tailormade and safe, non-drug, therapeutic solutions and non-invasive devices for the regeneration of musculoskeletal soft tissue to significantly improve patients’ well-being. The company provides a support structure to help medical and healthcare practitioners ensure that chronic patients are guided, evaluated and followed up.
Oxford Bioscience is working in close partnership with RedPlane by interpreting data received from practitioners whose patients use Elexoma™ Medic. Results, feedback and input about the product are gathered and interpreted by Oxford Bioscience; all part of the process of ensuring that both patient and practitioner receive the best from the Elexoma™ Medic. CME, the education journal of choice for general practitioners, currently runs a series of articles on microcurrent and CES and its treatment indications, to educate doctors about the value of this innovative treatment for their patients. [OBAP certificate]
The Oxford Bioscience Accreditation Programme (OBAP)
- The Oxford Bioscience Accreditation Programme enhances and supports the relationship between doctor and patient
- Oxford Bioscience offers a certificate testifying to the quality of service offered
The Oxford Bioscience Accreditation Programme (OBAP) benefits both the practitioner and patient. To comply with international Health Technology Assessment (HTA) requirements for medical devices, OBAP has been established to provide:
- A support structure for practitioners
- Patient guidance and evaluation
- Optimised utilisation and compliance
- Remuneration for evaluation reports
RedPlane offers all Oxford Bioscience-accredited medical and healthcare practitioners remuneration for evaluations and feedback on patients using Elexoma™ Medic. This feedback enables Oxford Bioscience to process the results for further research and assessment purposes. “We must use safe and cost-effective technology to achieve the goal of Quality Adjusted Life Years (QALY) for patients.” – Mr John Harvey, healthcare strategist.
Please visit our website for further information
